News | December 14, 2011

Blood-Based Gene Expression Test Beats MPI for Ruling Out Obstructive CAD

December 14, 2011 — The results of the COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) trial were presented at the American Heart Association Scientific Sessions 2011 conference in Orlando, Fla. This prospective, blinded multi-center study was designed to provide a third independent validation of the Corus CAD blood-based gene expression test.

The test is designed for ruling out obstructive coronary artery disease (CAD) in lower-risk patients with typical and atypical presentations of stable chest pain; it also compares the diagnostic performance of Corus CAD to myocardial perfusion imaging (MPI), a common test using a radioactive agent to evaluate blood flow and function of the heart.

"COMPASS builds on previous results of the PREDICT trial.  In this real-world patient population, the Corus CAD test demonstrates very high sensitivity and negative predictive value, enabling clinicians to rule out patients who do not have obstructive coronary artery disease with high accuracy,” said Gregory S. Thomas, M.D., M.P.H., clinical professor of medicine and director of nuclear cardiology education at the University of California-Irvine School of Medicine, who presented the findings.  “The use of this gene expression test, followed by MPI for higher scores, may optimize diagnostic performance and utilization of healthcare resources."
The trial enrolled 537 stable patients with symptoms suggestive of CAD who had been referred to MPI at 19 U.S. sites. A blood sample was obtained in all patients prior to MPI, and Corus CAD testing was then performed, with study investigators blinded to Corus CAD test results.

Following MPI, patients were referred either to invasive angiography or to computed tomography angiography (CTA); both are gold standard measurements of blood vessel lumen anatomy for diagnosis of coronary artery disease. A total of 431 patients were eligible for analysis, having completed gene expression testing, MPI and either invasive angiography or CTA.

In the study, Corus CAD was superior to MPI in diagnostic accuracy, sensitivity (89 percent vs. 27 percent, p<0.001) and negative predictive value (96 percent vs. 88 percent, p<0.001). It demonstrated excellent performance for ruling out obstructive coronary artery disease relative to both invasive angiography and CTA.  

In a March 11, 2010 study in The New England Journal of Medicine, 62 percent of nearly 400,000 patients who underwent elective invasive angiographic procedures were found to have no obstructive coronary artery blockage. The study authors concluded current modalities for identifying which patients should undergo elective invasive coronary angiography to diagnose CAD have limitations; subsequently, better methods are needed for patient risk stratification.

Corus CAD is the first and only clinically validated blood-based test for obstructive coronary artery disease. The test involves a routine blood draw administered in the clinician’s office and does not expose patients to risks of radiation or imaging agent intolerance.

It is a decision-making tool that can help primary care clinicians and cardiologists rule out obstructive CAD as the cause of a nondiabetic patient's symptoms. It is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women.

The Corus CAD test measures the RNA levels of 23 genes from a whole blood sample. These RNA levels are increased or decreased when obstructive CAD is present; as a result, the Corus CAD score indicates the likelihood an individual patient does not have obstructive CAD. 

It is commercially available through a patient sample kit that includes everything needed for blood collection and express delivery to the company’s CLIA-certified Palo Alto, Calif. laboratory. Test results are delivered promptly to the clinician’s office.

Corus CAD is currently available in the United States.

For more information:

Related Content

Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
Overlay Init